Medtronic cancels $738M acquisition of insulin-patch maker EOFlow

The deal for EOFlow, a Korean company that makes a wearable insulin patch, had been Medtronic's biggest M&A deal this year.

Previous How Falfurrias Capital Partners plans to use $400M raised for newly created fund
Next Washington Ho starts own brokerage, pitches real estate-focused 'House of Ho' spinoff